Crown laboratories announces completion of acquisition of revance therapeutics

The business combination reinforces crown's position as a leading, innovative, high-growth aesthetics and skincare company johnson city, tenn. , feb. 6, 2025 /prnewswire/ -- crown laboratories, inc. ("crown"), a privately held, global innovative leader in the skincare industry, today announced the successful closing of its acquisition of revance therapeutics, inc. ("revance") (nasdaq: rvnc), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings.
CCK Ratings Summary
CCK Quant Ranking